RNA Targeted Therapeutics Market

RNA Targeted Therapeutics Market Overview

The global RNA targeted therapeutics market size, valued at USD 1,764 million in 2025, is projected to reach USD 2,245 million in 2026 and USD 8,276 million by 2030, representing a CAGR of 38.6% during the forecast period, 2026 - 2030. 

To learn more about this report, request a free sample copy

Small molecule products presently dominate the overall pharmaceutical market, representing around 80% of the total pipeline candidates. In fact, in 2020, the USFDA approved 55 drugs, of which, over 65% were small molecule therapeutics. It is worth noting that majority of these drugs were conventionally developed to target proteins. However, reports suggest that merely 2% of the human genome is responsible for coding for proteins. Hence, the pharmaceutical industry is now focused on evaluating previously untapped targets, such as non-coding DNA and RNA; the latter molecules are expected to correspond to ~70% of the unknown portion of the human genome.

In recent past, RNA’s limitless potential as a target for small molecules, against a wide range of indications (both oncological and non-oncological), has been recognized. Specifically, a variety of small molecules that affect RNA function have been discovered. Further, many RNA riboswitch regulatory elements (capable of binding to a variety of small molecule metabolites and control gene expression) and small molecule antibiotics (having the ability to bind to ribosomal RNA and interfere with translation) have been identified. Consequently, drug developers are experimenting with RNA modification, RNA translation, RNA splicing, indirect RNA targeting (epitranscriptomics), and other ways to target RNA with small molecules. 

Currently, over 100 small molecule therapeutics, targeting RNA, are under development. Several experiments and clinical trials focused on RNA targeting antisense oligonucleotides (many of which have received regulatory approval), as well as preclinical studies for synthetic RNAs, which can redirect cellular RNA interference (RNAi) machinery or activate CRISPR-based systems, have demonstrated strong proof of principle for RNA targeting drugs. Moreover, a number of industry players (mostly small firms and start-ups) have developed their proprietary technologies for direct and indirect RNA targeting. Additionally, in the past five years, more than USD 800 million was invested in companies engaged in the development of RNA targeting small molecule therapeutics (primarily those developing candidates against oncological disorders). Many big pharma players, such as Pfizer, Novartis and Takeda Pharmaceutical, have also actively supported the initiatives taken by such drug developers, by making lucrative investments. Driven by encouraging clinical trial results, strategic collaborations and initiatives undertaken to expand expanding intellectual capital, this emerging market is expected to witness a steady market growth during the forecast period.

Key Companies in RNA Targeted Therapeutics Market 

Examples of key companies engaged in RNA targeted therapeutics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Abivax, AC immune, Arrakis Therapeutics, eFFECTOR Therapeutics, Eloxx Pharmaceuticals, H3 Biomedicine, PTC Therapeutics, Ribometrix, Skyhawk Therapeutics and STORM Therapeutics. This market report includes an easily searchable excel database of all the companies providing RNA targeted small molecules and RNA translation modulators, worldwide.

Recent Developments in RNA Targeted Therapeutics Market:

Several recent developments have taken place in the field of RNA targeted therapies market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In April 2026, xFOREST Therapeutics entered into a collaboration with Nippon Shinyaku focusing on RNA targeted small molecule therapeutics, leveraging xFOREST’s RNA splicing technology to develop compounds across multiple disease areas.
• In April 2026, xFOREST Therapeutics collaborated with Axcelead Drug Discovery to launch a joint research program to advance RNA targeted therapeutics, including RNA splicing modulators, with the aim of identifying novel small molecule drug candidates.
• In November 2025, Secarna Pharmaceuticals presented preclinical and translational data on its antisense oligonucleotide SECN 15, an RNA targeted therapeutic showing enhanced anti tumor immunity and potential for Phase I/II clinical development in gastric cancer.
• In October 2025, Secarna Pharmaceuticals partnered with Scenic Biotech entered a discovery and co development agreement to create an RNA targeted oligonucleotide therapy against a novel disease modifier target for rare genetic disorders. 

Scope of the Report

The “RNA Targeted Therapeutics Market by Type of Target, Type of Approach (Indirect RNA Targeting- Epitranscriptomics, mRNA Translation Modulation, RNA Splicing Modification), Target Indication (Aniridia, Breast Cancer, Castrate-resistant Prostate Cancer, Colorectal Cancer, Crohn Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Dravet Syndrome, Epilepsy, HIV Infections, Impaired Renal Function, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Spinal Muscular Atrophy, Ulcerative Colitis), Target Therapeutic Area (Autoimmune Disorders, Genetic Disorders, Infectious Disorders, Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Ophthalmic Disorders, Rare Disorders, Renal Disorders, Respiratory Disorders), Route of Administration (Oral and Subcutaneous Injection) and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, till 2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the RNA targeted therapeutics market. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in RNA targeted therapies market. Amongst other elements, the market research report includes:

• A detailed overview of the current market landscape of RNA targeting small molecule therapeutics, including information on phase of development (clinical and preclinical), target disease indication(s), therapeutic area (non-oncological disorders and oncological disorders), target molecule (BMI1, cap binding complex,  eLF4A, MNK1 / MNK2, VEGF, others), type of approach (indirect RNA targeting – epitranscriptomics, mRNA translation modulation, RNA splicing modification) and route of administration (intravenous, subcutaneous biologics and oral). In addition, it highlights the developers of these novel therapeutics, along with information on their year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary drug candidates.
• An in-depth analysis of the company competitiveness and investment landscape, including a bubble analysis comparing the key players engaged in the domain of RNA targeting small molecules, based on several relevant parameters (such as company experience, pipeline strength, partnership activity, funding activity, patents filed and company size) and a multivariate representation illustrating the start-ups and investment activity based on various multiple parameters (such as funding type, therapeutic area and amount invested).
• Elaborate profiles of key players engaged in the development of RNA targeting small molecule therapeutics. Each profile features a brief overview of the company, recent developments and an informed future outlook.
• An analysis of the recent collaborations and partnerships that have been inked between various stakeholders in RNA targeted therapeutics market, since 2017, covering R&D agreements, clinical trial agreements, acquisitions, licensing agreements and product development agreements.
• An analysis of the investments made, since 2015, including grant, seed financing, venture capital financing, initial public offering (IPO), debt financing and other equity, in companies that are engaged in the development of RNA targeting small molecule therapeutics.

The key objective of RNA targeted therapeutics market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for RNA targeted therapies market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the forecast period till 2030. The market report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of target molecule (cap binding complex, CDKL5, dystrophin protein, Erα, G542X, MNK1 / MNK2, PAX6 gene, SMN2) [B] type of approach (indirect RNA targeting- epitranscriptomics, mRNA translation modulation, RNA splicing modification) [C] target indication (aniridia, breast cancer, castrate-resistant prostate cancer, colorectal cancer, Crohn disease, cystic fibrosis, Duchenne muscular dystrophy, Dravet syndrome, epilepsy, HIV infections, impaired renal function, non-small cell lung cancer, rheumatoid arthritis, spinal muscular atrophy, ulcerative colitis) [D] target therapeutic area (autoimmune disorders, genetic disorders, infectious disorders, inflammatory disorders, neurological disorders, oncological disorders, ophthalmic disorders, rare disorders, renal disorders, respiratory disorders), [E] route of administration (oral and subcutaneous injection) and [E] region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the market report were also influenced by discussions held with multiple stakeholders in RNA targeted therapeutics market. The market research report features detailed transcripts of interviews held with the following individuals

• Business Development, US-based Mid-sized Company
• President / Co-Founder, Canada-based Small Company

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.